Clarus Group’s RxSight RXST Stock Holding History

Clarus Group’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,000	Closed	-$247K	–	108
2024 Q3	$247K	Hold	5,000	–	–	0.1%	95
2024 Q2	$301K	Hold	5,000	–	–	0.13%	84
2024 Q1	$258K	Hold	5,000	–	–	0.18%	92
2023 Q4	$202K	Buy	+5,000	New	+$147K	0.15%	98

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Clarus Group's RXST Position: Q4 2024 in Review

Clarus Group sold out of RxSight (RXST) in Q4 2024, closing a stake of 5,000 shares — an estimated $247K sold.

Clarus Group first reported a position in RXST in Q4 2023 and held it in 4 quarters. The position peaked at $301K in Q2 2024. 212 funds tracked by Wall St. Rank hold RXST as of Q4 2024.

Clarus Group reported no remaining RxSight position as of Q4 2024 after selling out during the quarter.
Clarus Group sold 5,000 RxSight shares in Q4 2024, an estimated $247K.
Clarus Group first reported a position in RxSight in Q4 2023 and held it in 4 quarters.
Clarus Group's RxSight position peaked at $301K in Q2 2024.
212 funds tracked by Wall St. Rank held RxSight as of Q4 2024.

Based on Clarus Group's 13F filing for Q4 2024, filed 29 Jan 2025.